Prognostic significance of latent membrane protein 1 expression in non-Hodgkin lymphoma
A meta-analysis
Xiao-Mei Li, MDa, Wen-Hua Xiao, MDb,∗, Hui-Xia Zhao, MDb

Abstract

Background: The prognostic value of latent membrane protein 1 (LMP1) in non-Hodgkin lymphoma (NHL) has been evaluated in several studies. However, the conclusions remain controversial.

Methods: We searched relevant literatures from Embase, PubMed, and China National Knowledge Infrastructure Platform databases and performed a meta-analysis to evaluate the prognostic significance of LMP1 expression in NHL. Pooled hazard ratio (HR), 95% confidence interval (CI), and P value were calculated. Nine relevant studies were analyzed in this meta-analysis. We performed a pooled analysis to assess the association between LMP1 expression and overall survival of NHL patients.

Results: Our results revealed that LMP1-positive NHL patients had significantly poorer outcomes than LMP1-negative patients (HR = 2.13, 95% CI = 1.31–3.46, P heterogeneity = 0.005, I² = 63.5%). Furthermore, in the subgroup analysis stratified by country, a statistically significant association was found among Chinese (HR = 2.80, 95% CI = 1.53–5.15, P heterogeneity = 0.342, I² = 6.9%); however, no statistically significant relations were found among Japanese (HR = 1.55, 95% CI = 0.74–3.24, P heterogeneity = 0.020, I² = 65.7%).

Conclusion: The expression of LMP1 can be considered a poor predictor of survival in patients with NHL. In addition, LMP1 expression assessment could provide more detailed information for patients with NHL and could be used to optimize therapeutic schemes.

Abbreviations: CI = confidence interval, EBV = Epstein–Barr virus, HR = hazard ratio, IHC = immunohistochemistry, LMP = latent membrane protein, LMP1 = latent membrane protein 1, NHL = non-Hodgkin lymphoma, OS = overall survival, TNF = tumor necrosis factor.

Keywords: Epstein–Barr virus, latent membrane protein 1, meta-analysis, non-Hodgkin lymphoma

1. Introduction

Non-Hodgkin lymphoma (NHL) is the most common malignancy of the blood system in the world.[1] It is more common in developed countries, and in 2014 there were 70,800 new cases in the United States. NHL, which accounts for 4.3% of all cancers in the US, is listed as the 7th most common cancer in men and the 6th most common cancer among women.[2,3] In China, NHL represents approximately 2% of new cancer cases diagnosed each year, becoming the 8th most common cancer and the 10th largest cause of cancer deaths.[4,5]

NHL is a heterogeneous group of malignant lymphomas. For the development of NHL, immune suppression is the most important risk factor. The risk of developing high-grade NHL is increased in patients with human immunodeficiency virus. Other risk is increased, including organ transplantation, stem cell transplantation in patients with high-dose chemotherapy, and those with genetic immune deficiency syndrome or autoimmune disease.[6,7] Infection does play a role in the development of certain lymphomas, either by suppressing immune function or through other mechanisms, such as chronic inflammatory induced. Epstein–Barr virus (EBV), for example, has been recognized with Burkitt and nasal NK-cell or T-cell lymphoma, and Helicobacter pylori as a risk factor in association with infections related to gastric mucosa-associated lymphoid tissue lymphoma.

EBV is an important paradigm for transforming viruses in several NHL subtypes.[8] The expression of EBV in NHL can be detected by immunohistochemical identification of EB virus latent membrane protein (LMP). The role of EBV as the etiological agent in the development of NHL has been supported by detecting high levels of LMP1 expression in these tumors.[9] There are several studies assessing the prognostic role of LMP1 expression in NHL, and no consistent outcomes are reported.[10–18] To provide a comprehensive assessment of the prognostic role of LMP1 expression in NHL, we performed a meta-analysis of published studies.
2. Materials and methods

Ethical approval for this study was not unnecessary since it was a meta-analysis that collect and analysis data from the existing literatures.

2.1. Search strategy

We searched for relevant studies up to May 2015 through the PubMed, Embase, and China National Knowledge Infrastructure Platform (CNKI; http://www.cnki.net) database with the following terms and their combinations: “lymphoma/non-Hodgkin lymphoma,” “Epstein–Barr virus/EB virus,” “latent membrane protein 1/LMP-1,” and “prognosis/survival.” All scanned abstracts, studies, and citations were reviewed. Moreover, references of the retrieved manuscripts were also manually cross-searched for further relevant publications.

2.2. Selection criteria

The inclusion criteria included: be on patients with NHL; provide overall survival (OS) data to evaluate the role of LMP1 expression in the prognosis of NHL patients; and provide hazard ratios (HRs) with 95% confidence intervals (CIs) or enable calculation of these statistics from the data presented. The exclusion criteria included: the studies which used the same population or overlapping database; the studies of in vitro cell culture models.

2.3. Data extraction

Two independent investigators extracted the original data according to the inclusion criteria and exclusion criteria to ensure the accuracy of the retrieved information. The following data were collected from each study: first author name, publication year, country where the research was performed, number of patients, histology, detection method, antibody used and its dilution, cutoff value for positivity, and OS data.

2.4. Statistical analysis

Previously reported indirect methods were used to extract the log HR (logHR) and variance due to the few prognostic literature, which report these values directly. These values were calculated either from the HR and 95% CI in the reference, the log rank P-value, or directly from the Kaplan–Meier curves. When an HR and 95% CI were not available in the study, estimated values were obtained indirectly using Kaplan–Meier curves described by Tierney et al. Kaplan–Meier curves were read by an Engauge Digitizer, version 4.1 (http://digitizer.sourceforge.net/), and the data from the curves were entered in the spreadsheet appended to Tierney et al’s report. Q-test results of $P<0.10$ suggested significant heterogeneity among studies, so the pooled HR of all studies was calculated using the random-effects model based on DerSimonian–Laird method; otherwise, the fixed-effects model based on Mantel–Haenszel method was conducted. Meta-regression was performed to detect the source of heterogeneity by country, histological type, size of study, detection method, and cutoffpoint. Between studies, variance Tau-squared ($\tau^2$) value was used to evaluate the degree of heterogeneity, and the $I^2$ was used to describe the extent of heterogeneity explained. We also performed sensitivity analysis by omitting an individual study each time to check whether any of these estimates can bias the overall estimate. The evaluation of potential publication bias was performed using the Begg funnel plots and Egger test ($P<0.05$ was regarded as representative of statistical significance). All the data management and analysis for this meta-analysis were performed with STATA 12.0 software (Stata corporation, College Station, TX), and all tests were 2-sided.

3. Results

3.1. Characteristics of the studies

The literature search yielded 216 articles at initial screening. After exclusion of 172 irrelevant articles, the remaining articles were systematically reviewed, and 21 articles were chosen for full-text reading. After full-text reading, 12 articles were further excluded due to the reasons indicated in Fig. 1. Therefore, 9 independent studies composed of 417 NHL patients were finally collected in this meta-analysis. The flow chart of literature search and study selection was illuminated in Fig. 1. The main characteristics of these included studies were shown in Table 1.

3.2. Quantitative synthesis

All 9 studies including 417 patients explored the prognostic significance of latent membrane protein 1 (LMP1) expression in NHL. We performed pooled analysis with available data on the correlation between LMP1 expression and OS. The main results of this meta-analysis were showed in Table 2. The pooled results showed that LMP1-positive NHL patients had significantly poorer outcomes than LMP1-negative patients (HR = 2.13, 95% CI = 1.31–3.46, $P_{\text{heterogeneity}} = 0.005$, $I^2 = 63.5\%$) (Fig. 2). In the subgroup analysis stratified by country, a statistically significant association was found among Chinese (HR = 2.80, 95% CI = 1.53–5.15, $P_{\text{heterogeneity}} = 0.342$, $I^2 = 6.9\%$); however, no statistically significant relations were found among Japanese (HR = 1.55, 95% CI = 0.74–3.24, $P_{\text{heterogeneity}} = 0.020$, $I^2 = 65.7\%$) (Fig. 3). Moreover, we performed subgroup analyses according to histological type, size of study, detection method, and cutoffpoint. In subgroup analysis based on histological type, a statistically significant association was found in NHL (HR = 3.11, 95% CI = 1.76–5.49, $P_{\text{heterogeneity}} = 0.858$, $I^2 = 0\%$); however, no statistically significant relations were found in ENKL (HR = 2.32, 95% CI = 0.63–8.49, $P_{\text{heterogeneity}} = 0.003$, $I^2 = 78\%$) (Table 2). In subgroup analysis based on size of study, a statistically significant association was found in ≥50 group (HR = 2.68, 95% CI = 1.73–4.41, $P_{\text{heterogeneity}} = 0.715$, $I^2 = 0\%$); however, no statistically significant relations were found in <50 group (HR = 1.86, 95% CI = 0.88–3.95, $P_{\text{heterogeneity}} = 0.009$, $I^2 = 67.6\%$) (Table 2). In subgroup analysis based on detection method, a statistically significant association was found in immunohistochemistry (IHC) group (HR = 2.11, 95% CI = 1.19–3.74, $P_{\text{heterogeneity}} = 0.056$, $I^2 = 51.1\%$); however, no statistically significant relations were found in other group (HR = 2.63, 95% CI = 0.56–12.39, $P_{\text{heterogeneity}} = 0.015$, $I^2 = 83.1\%$) (Table 2). In subgroup analysis based on cutoffpoint, a statistically significant association was found in yes group (HR = 2.71, 95% CI = 1.39–5.27, $P_{\text{heterogeneity}} = 0.016$, $I^2 = 67\%$); however, no statistically significant relations were found in no group (HR = 1.46, 95% CI = 0.56–3.76, $P_{\text{heterogeneity}} = 0.026$, $I^2 = 67.8\%$) (Table 2).

3.3. Evaluation of heterogeneity

There was heterogeneity among studies in overall comparisons and also subgroup analyses. Meta-regression revealed that country,
histological type, size of study, detection method, and cutpoint did not contribute to the source of heterogeneity (τ² > 0.05).

3.4. Sensitivity analysis

Sensitivity analysis was performed to investigate the influence of each study on the overall HRs, and the result showed that no individual study affected the overall HR dominantly, since the omission of any single study made no substantial difference (Fig. 4). This procedure confirmed the stability of the overall result.

3.5. Publication bias

Finally, the Egger regression test showed no evidence of asymmetrical distribution in the funnel plot in LMP1 expression in NHL (Begg test P = 0.754; Egger test P = 0.221) (Fig. 5).

Table 1

| Authors/year of publication | Country | Histological type | No of patients (LMP1+/LMP1+) | Method | Cutpoints | HRs |
|-----------------------------|---------|-------------------|-------------------------------|--------|-----------|-----|
| Kuze/1996[10]               | Japan   | BCL               | 6/11                          | IHC    | NA        | 1.77 (0.29–10.70) |
| Yamamoto/1999[11]           | Japan   | TCL               | 15/10                         | ISH    | mRNA positive | 1.34 (1.02–1.75) |
| Cao/2003[12]                | China   | NHL               | 48/22                         | IHC    | Percentage of positive cells, >5% | 3.42 (1.03–11.41) |
| Hirose/2006[13]             | Japan   | PTCL              | 14/29                         | IHC    | NA        | 1.91 (0.78–4.69) |
| Ishii/2007[14]              | Japan   | ENKL              | 13/7                          | Real-time PCR ≥4 copies/ml | 6.63 (1.88–23.41) |
| Cao/2008[15]                | China   | ENKL              | 47/11                         | IHC    | Percentage of positive cells, ≥10% | 2.16 (1.01–3.96) |
| Paydas/2008[16]             | Turkey  | NHL               | 20/118                        | IHC    | NA        | 3.02 (1.58–5.75) |
| Kanemitsu/2012[17]          | Japan   | ENKL              | 22/8                          | IHC    | NA        | 0.28 (0.06–0.96) |
| Mao/2012[18]                | China   | ENKL              | 9/7                           | IHC    | Staining intensity ≥1 | 8.75 (1.41–54.48) |

BCL = anaplastic large cell lymphoma of B-cell type, ENKL = extranodal NK/T-cell lymphoma, HR = hazard ratio, IHC = immunohistochemistry, ISH = in situ hybridization, NA = not available, NHL = non-Hodgkin lymphoma, PCR = polymerase chain reaction, PTCL = peripheral T-cell lymphomas, TCL = T-cell lymphoma.
4. Discussion

EBV, also known as human herpesvirus 4, establishes mainly latent infection based on B lymphocytes, but it can also infect other types of cells, including the NK cells, T cells, and epithelial cells. EBV infection as a causal factor has been implicated in a variety of malignant tumors, including lymphoma and virus encoded latent gene expression patterns, depending on the origin and the state of the tumor.\(^{21}\) The first protein from EBV having its carcinogenic nature by experience confirmed is LMP1,\(^{22}\) which is expressed on the cell surface, where it spontaneously gathered to form a constitutive activation of the receptor expression, as a member of the tumor necrosis factor (TNF) receptor family, and allows the LMP1 exert influence on cells with different intracellular signaling cascade of cellular and molecular interactions involved.\(^{23-26}\) Recently, a growing number of studies have investigated the prognostic significance of LMP1 expression in NHL; however, the results are conflicting. A possible explanation is that Epstein–Barr encoding region in situ hybridization and LMP1 IHC are widely used methods for identifying EBV in tumor cells; however, some errors about these methods are relevant.\(^{27,28}\) For this reason results are highly variable and the comments about the EBV and NHLs are highly different. Furthermore, certain epidemiologic factors (eg, age, gender, etc.) and the extent of LMP1 expression are critical in determining the prognosis of NHL patients. Therefore, further studies are needed to clarify the prognostic value of LMP1 expression in NHL.

### Table 2

| Study characteristics | No of patients (LMP1+/LMP1 -) | HR (95%CI) | I\(^2\), % | P for heterogeneity |
|-----------------------|-------------------------------|------------|------------|---------------------|
| Total (N=9)           | 194/223                       | 2.13 (1.31–3.46) | 63.5       | 0.005              |
| Country: Japan (N=5)  | 70/85                         | 1.55 (0.74–3.24) | 65.7       | 0.020              |
| China (N=3)           | 104/40                        | 2.80 (1.53–5.15) | 6.9        | 0.342              |
| Turkey (N=1)          | 20/118                        | 3.02 (1.58–5.76) | –          | –                  |
| Histological type: EKM (N=4) | 91/33       | 2.32 (0.63–8.49) | 78         | 0.003              |
| NHL (N=2)             | 66/140                        | 3.11 (1.76–5.49) | 0          | 0.858              |
| Other (N=3)           | 35/50                         | 1.39 (1.07–1.79) | 0          | 0.733              |
| Size of study <50 (N=6) | 79/72              | 1.86 (0.88–3.98) | 67.6       | 0.009              |
| ≥50 (N=3)             | 115/151                       | 2.68 (1.73–4.41) | 0          | 0.715              |
| Method: IHC (N=7)     | 166/206                       | 2.11 (1.19–3.74) | 51.1       | 0.056              |
| Other (N=2)           | 28/17                         | 2.63 (0.56–12.39) | 83.1       | 0.015              |
| Cutpoints yes (N=5)   | 132/57                        | 2.71 (1.39–5.27) | 67         | 0.016              |
| No (N=4)              | 62/166                        | 1.46 (0.56–3.76) | 67.8       | 0.026              |

CI = confidence interval, ENKL = extranodal NK/T-cell lymphoma, HR = hazard ratio, IHC = immunohistochemistry, LMP1 = latent membrane protein 1, NHL = non-Hodgkin lymphoma.

**Figure 2.** HRs and 95% CI of individual studies and pooled data for the association of LMP1 expression and OS in NHL patients. CI = confidence interval, HR = hazard ratio, LMP1 = latent membrane protein, NHL = non-Hodgkin lymphoma, OS = overall survival.
Figure 3. Forest plot of the HRs and 95% CIs of studies on the association of LMP1 expression and OS with country in NHL patients. CI = confidence interval, HR = hazard ratio, LMP1 = latent membrane protein 1, NHL = non-Hodgkin lymphoma, OS = overall survival.

Figure 4. The influence of individual studies on the summary HRs. The middle vertical axis indicates the overall HRs and the 2 vertical axes indicate its 95% CI. Every hollow round indicates the pooled HRs when the left study was omitted in this meta-analysis. The 2 ends of every broken line represent the 95% CI. CI = confidence interval, HR = hazard ratio.
geographical factors, socioeconomic status, and so on) might influence the prognostic impact of LMP1 expression in NHLs.\[28,30\] In order to obtain a comprehensive conclusion, we retrieved the relevant literature and performed a meta-analysis.

Meta-analysis is a systematic review that uses quantitative methods to synthesize and summarize the results from related studies.\[31,32\] Most meta-analyses are based on one of 2 models, the fixed-effect statistical model or a random effects statistical model. The fixed-effects model assumes that all included studies investigate the same population and estimate the same treatment effect. That is to say, there is no between-study heterogeneity in the true intervention effect. The meaning of this pattern is that the observed changes in the therapeutic effect are only due to the difference in opportunity from sampled patients. In this study, if the P-value of the Q-test >0.10, we chose a fixed-effects model. The random effects meta-analysis model assumes that the observed therapeutic effects can be estimated differently depending on the actual differences in the therapeutic effect in each study, as well as the sampling variability. Therefore, even though all studies had an infinite sample size, the observed effects of the study will still vary because of the real difference in treatment outcomes. This heterogeneity of therapeutic effect is due to differences in study population, length of follow-up, interventions, and other factors. Therefore, when the P-value of the Q-test is <0.10, we chose a random-effects model.

The results of our meta-analysis showed significant correlations of LMP1 expression with OS in NHL (HR=2.13, 95% CI=1.31–3.46, \(P_{\text{heterogeneity}}=0.005, I^2=63.5\%\)), implying that the expression of LMP1 can be considered a prognostic biomarker in NHL. This is consistent with the findings of previous studies that have shown that LMP1 expression is associated with worse OS in NHL.\[33,34\] Therefore, we conducted a meta-analysis to further investigate the prognostic significance of LMP1 expression in NHL.

References

[1] Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://gbo.nci.iarc.fr
[2] Surveillance, Epidemiology, and End Results (SEER) Program. National Cancer Institute, DCCPS, Cancer Statistics Branch 2011. Available from: www.seer.cancer.gov [updated based on the November 2010 submission]
[3] Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2009), National Cancer Institute, DCCPS, Cancer Statistics Branch 2011. Available from: www.seer.cancer.gov/popdata
[4] Chen WQ, Zhang SW, Zou XN, et al. Cancer incidence and mortality in China, 2006. Clin J Cancer Res 2011;23:3–9.
[5] Chen W, Zheng R, Zhang S, et al. Report of incidence and mortality in China cancer registries, 2009. Clin J Cancer Res 2013;25:10–21.
[6] Jaffe ES, Harris NL, Stein H, et al. World Health Organization Classification of TumoursPathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon:2001.

[7] Haraldsson L, Eriksson M. Is the decline of the increasing incidence of non-Hodgkin lymphoma in Sweden and other countries a result of cancer preventive measures? Environ Health Perspect 2003;11:1704–6.

[8] Beltran BE1, Morales D, Quiñones P, et al. EBV-positive diffuse large B-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk 2011;11:512–6.

[9] Matsushita H, Nakamura N, Tanaka Y, et al. Clinical and pathological features of B-cell non-Hodgkin lymphomas lacking the surface expression of immunoglobulin light chains. Clin Chem Lab Med 2012;50:1665–70.

[10] Kuze T, Nakamura N, Hashimoto Y, et al. Clinicopathological, immunological and genetic studies of CD30+ anaplastic large cell lymphoma of B-cell type: association with Epstein-Barr virus in a Japanese population. J Pathol 1996;180:236–42.

[11] Yamamoto T, Nakamura Y, Kishimoto K, et al. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1. Virus Res 1999;65:43–55.

[12] Cao W, Zhang L. The expression and significance of latent membrane protein 1 expression in non-Hodgkin’s lymphoma [Article in Chinese]. Zhongguo Zhong Liu Lin Chuang 2003;11:791–6.

[13] Hirono Y, Masaki Y, Sawaki T, et al. Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. Eur J Haematol 2006;76:109–18.

[14] Ishii H, Ogino T, Berger C, et al. Clinical usefulness of serum EBV DNA levels of BamHI-W and LMP1 for Nasal NK/T-cell lymphoma. J Med Virol 2007;79:562–72.

[15] Cao W, Liu Y, Zhang H, et al. Expression of LMP-1 and cyclin D protein is correlated with an unfavorable prognosis in nasal type NK/T cell lymphoma. Mol Med Rep 2008;1:363–8.

[16] Paydas S, Ergin M, Erdogan S, et al. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin’s lymphomas. Leuk Res 2008;32:1424–30.

[17] Kanemitsu N, Isobe Y, Masuda A, et al. Expression of Epstein-Barr virus-encoded proteins in extranodal NK/T-cell Lymphoma, nasal type (ENKTL): differences in biologic and clinical behaviors of LMP1-positive and -negative ENKTL. Clin Cancer Res 2012;18:2164–72.

[18] Yuan M, Zhang DW, Zhu H, et al. LMP1 and LMP2A are potential prognostic markers of extranodal NK/T-cell lymphomas, nasal type (ENKTL). Diagn Pathol 2012;7:1–8.

[19] Parmar MK, Torrisi V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 2009;28:2815–34.

[20] Tierney JF, Stewart LA, Gherisi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.

[21] Murata T, Noda C, Narita Y, et al. Induction of Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1) by transcription factors activating protein 2 (AP-2) and early B cell factor (EBF). J Virol 2016;90:3873–89.

[22] Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:381–40.

[23] Kilger E, Kieser A, Baumann M, et al. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998;17:1700–9.

[24] Tsao SW, Tramontanis G, Dawson CW, et al. The significance of LMP1 expression in nasopharyngeal carcinoma. Semin Cancer Biol 2002;12:473–87.

[25] Morris MA, Dawson CW, Young LS. Role of the Epstein–Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol 2009;5:811–25.

[26] Li HP, Chang YS. Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003;10:490–504.

[27] Glaser SL, Gulley ML, Borowitz MJ, et al. Inter and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma 2004;45:489–547.

[28] Kanemitsu N, Isobe Y, Masuda A, et al. Expression of Epstein-Barr virus-positive and -negative ENKL. Clin Cancer Res 2012;18:2164–72.

[29] Egger M, Davey Smith G. Meta-analysis: potentials and promise. BMJ 1997;315:1371–4.

[30] Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. John Wiley 2000;14:3–17.

[31] Kieff ED, Rickinson AB, Kipreos ET, et al. Epstein-Barr virus and the pathogenesis of B-cell lymphomas. Ann Rev Pathol 2007;2:41–68.

[32] Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Immunol 2005;5:463–8.

[33] Sallusto F, Lanzavecchia A. Two subsets of memory CD8+ T lymphocytes: Th1/Th2 and Tc1/Tc2 subtypes. Eur J Immunol 2000;30:2273–80.

[34] Rickinson AB. Epstein-Barr virus (EBV) and the pathogenesis of epithelial cell lymphomas. Leuk Res 2004;28:1693–700.